Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for
Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation. Exton, PA., November 15,
The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s
Spherix Global Insights’ White Paper Highlights MarketExpansion and Strategies for Opportunities in HS. Exton, PA, November 7, 2024 — Spherix
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra
Systemic sclerosis is the most challenging diagnosis to make among rheumatic and autoimmune conditions, according to 91% of respondents in
US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights. EXTON, PA., November
More than half of dermatomyositis patients are not optimally managed, according to a survey of 102 U.S. rheumatologists and dermatologists
Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists
With the potential rise of new oral agents, dermatologists are increasingly optimistic about safer, more convenienttreatment options for psoriasis, according
Incorporation of gene therapies, such as Beqvez (Pfizer),Hemgenix (CSL Behring) and Roctavian (BioMarin), and potential future approvalsof fitusiran (Sanofi) and
Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in
